Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Last trade$0.4367
Day change-$0.0692 (-13.68%)
Day range$0.435 – $0.509
Volume2,500,231
Market cap$78M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$78.81M
Price / earnings
—
Price / book
3.12×
Price / sales
1.47×
EV / sales
1.45×
EV / EBITDA
-0.54×
Profitability
Earnings per share
-$0.88
Return on assets
-79.45%
Return on equity
-538.38%
Dividend yield
0%
Liquidity and leverage
Debt / equity
2.08×
Current ratio
1.51×
Quick ratio
1.45×
Cash ratio
0.71×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$652.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CHRS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$14.27M
$14.31M
$12.31M
$12.75M
$11.57M
$10.25M
$7.6M
$7.73M
Cost of revenue
$4.09M
$4.24M
$3.81M
$4.05M
$3.72M
$3.4M
$2.65M
$2.75M
Gross profit
$10.18M
$10.07M
$8.5M
$8.7M
$7.85M
$6.86M
$4.95M
$4.98M
Selling, general and administrative
$21.23M
$20.95M
$23.1M
$23.61M
$24.93M
$26.04M
$26.03M
$29.61M
Research and development
$22.61M
$21.44M
$21.54M
$30.97M
$27.25M
$26.31M
$24.36M
$20.76M
Total operating expenses
$43.83M
$42.4M
$44.65M
$54.58M
$52.18M
$52.35M
$50.38M
$50.37M
Operating income
-$33.65M
-$32.33M
-$36.15M
-$45.88M
-$44.33M
-$45.49M
-$45.44M
-$45.38M
Interest expense
-$2.78M
-$2.32M
-$2.19M
-$2.25M
-$2.33M
-$2.28M
-$2.15M
-$1.91M
Income before taxes
-$38.88M
-$33.35M
-$36.94M
-$46.35M
-$44.52M
-$44.86M
-$47.4M
-$46.09M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$39.33M
-$20.63M
-$38.33M
-$37.64M
-$35.53M
$297.77M
-$56.57M
-$50.7M
Net income attributable to common shareholders
-$39.33M
-$20.63M
-$38.33M
-$37.64M
-$35.53M
$297.77M
-$56.57M
-$50.7M
EBITDA
-$32.8M
-$31.47M
-$35.27M
-$44.98M
-$43.37M
-$44.47M
-$44.39M
-$44.35M
Basic earnings per share
-$0.25
-$0.13
-$0.28
-$0.31
-$0.31
$2.57
-$0.49
-$0.44
Diluted earnings per share
-$0.25
-$0.13
-$0.28
-$0.31
-$0.31
$2.57
-$0.49
-$0.44
Recent news
Company coverage with links to the original publishers.
Coherus Oncology announced a 30% workforce reduction to lower quarterly operating costs by $6-7 million, reducing the revenue needed for cash breakeven from $30-35 million to $25-30 million per quarter. The company is narrowing clinical development of tagmokitug to second-line esophageal cancer treatment. LOQTORZI achieved $14 million in Q3 net sales with 25% year-over-year growth, and 75% of surveyed oncologists now view it as standard-of-care treatment for nasopharyngeal carcinoma. However, with less than 12 months of cash runway, execution and sales growth are critical for survival.
Coherus Oncology reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.22, with revenues of $14.27 million falling 10.25% short of expectations. The stock has declined 45.8% year-to-date, significantly underperforming the S&P 500's 7.8% gain. Despite the miss, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
Coherus Oncology announced it will release second quarter 2026 financial results on August 5, 2026, followed by a conference call at 5:00 p.m. EDT. The company will discuss financial performance and provide a business update on its oncology pipeline, including its approved PD-1 inhibitor LOQTORZI and mid-stage clinical candidates.
Coherus Oncology and Zumutor Biologics announced a Phase 1 clinical collaboration to evaluate ZM008, an anti-LLT1 monoclonal antibody, in combination with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, in patients with various solid tumors. The trial will enroll up to 45 patients and aims to evaluate safety, tolerability, and identify biomarkers for personalized therapies. Both companies retain commercial rights to their respective compounds.
Coherus Oncology completed a public offering of 28.6 million shares at $1.75 per share, raising approximately $50.1 million in gross proceeds. The company plans to use the funds to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of pipeline candidates, and for general corporate purposes. The offering was led by healthcare investors including Janus Henderson, HBM Healthcare Investments, and Samsara BioCapital.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.